| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/03/2011 | US20110052500 TAJ in Neuronal Function |
| 03/03/2011 | US20110052498 Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders |
| 03/03/2011 | US20110052493 Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-a of hmgb1 to prevent and/or antagonize pathologies induced by hmgb1 |
| 03/03/2011 | CA2772489A1 Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders |
| 03/03/2011 | CA2772379A1 Antibodies that bind tau oligomers |
| 03/03/2011 | CA2772294A1 Methods for the prevention and treatment of cerebral ischemia |
| 03/03/2011 | CA2772169A1 (thio)morpholine derivatives as s1p modulators |
| 03/03/2011 | CA2772168A1 Anhydrate forms of a pyridine derivative |
| 03/03/2011 | CA2772093A1 Np-1 antagonists and their therapeutic use |
| 03/03/2011 | CA2770480A1 Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| 03/03/2011 | CA2767770A1 Pyrrolidine derivatives as nk3 receptor antagonists |
| 03/02/2011 | EP2290079A2 Neurotrophic factors |
| 03/02/2011 | EP2289970A1 Biocompatible polymers, their process of manufacture and compositions containing them |
| 03/02/2011 | EP2289941A2 Administration of agents for the treatment of inflammation |
| 03/02/2011 | EP2289911A2 Therapeutic use of a growth factor, NsG33 |
| 03/02/2011 | EP2289882A1 3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments |
| 03/02/2011 | EP2289879A1 Synthesis of a crytalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt |
| 03/02/2011 | EP2289551A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/02/2011 | EP2289549A2 Immunoconjugates for treating cancer |
| 03/02/2011 | EP2289545A2 Supplemented OMV vaccine against meningococcus |
| 03/02/2011 | EP2289542A1 Treatment of neurological or neurodegenerative disorders |
| 03/02/2011 | EP2289541A1 Treatment of neurological or neurodegenerative disorders |
| 03/02/2011 | EP2289537A1 PDGF for use in the treatment of central nervous system disorders |
| 03/02/2011 | EP2289531A2 Medicaments for increasing endogenous erythropoietine (EPO) |
| 03/02/2011 | EP2289529A1 Nigella extracts for the treatment of disorders connected to impaired or imbalanced neurotransmission |
| 03/02/2011 | EP2289528A1 Novel nutraceutical compositions containing black pepper or its constituents improving mental performance |
| 03/02/2011 | EP2289526A1 Muscle derived cells (MDCs) for promoting and enhancing nerve repair and regeneration. |
| 03/02/2011 | EP2289519A2 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| 03/02/2011 | EP2289517A2 Controlled release oxycodone compositions |
| 03/02/2011 | EP2289514A1 Pramipexole once daily dosage form |
| 03/02/2011 | EP2289511A1 Use of retinoids for treatment or prevention of Alzheimer's Disease |
| 03/02/2011 | EP2289504A2 SIRT1 modulators for manipulating cell/organism lifespan/stress response |
| 03/02/2011 | EP2289503A2 Treating muscle wasting with selective androgen receptor modulators |
| 03/02/2011 | EP2289500A1 Retinol binding protein and transthyretin modulators for treating hypertosis, Alzheimer's disease or idiopathic intracranial hypertension |
| 03/02/2011 | EP2289498A1 Use of inhibitors of glutaminyl clyclase |
| 03/02/2011 | EP2289489A2 Compositions comprising cyclohexylamines and aminoadamantanes |
| 03/02/2011 | EP2289488A2 Remedies for diseases to be applied to eye |
| 03/02/2011 | EP2288613A1 Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use |
| 03/02/2011 | EP2288612A1 Gabaa receptor modulators |
| 03/02/2011 | EP2288608A1 Novel oxadiazolyl-diazabicyclononane derivatives and their medical use |
| 03/02/2011 | EP2288607A1 Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| 03/02/2011 | EP2288605A1 Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| 03/02/2011 | EP2288604A1 Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| 03/02/2011 | EP2288603A1 Tetrazole compounds as orexin receptor antagonists |
| 03/02/2011 | EP2288350A1 Method of treatment with potentised stereoisomer of glutamate |
| 03/02/2011 | EP2288347A1 Use of enantiomer (1s, 2r) of milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients |
| 03/02/2011 | EP2288345A1 Psycho-pharmaceuticals |
| 03/02/2011 | EP2288334A1 Composition and method for transmucosal delivery of lofexidine |
| 03/02/2011 | EP2081904B1 Aripiprazole hemifumarate and process for its preparation |
| 03/02/2011 | EP2069332B1 Azetidine compounds as orexin receptor antagonists |
| 03/02/2011 | EP2066685B1 Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
| 03/02/2011 | EP1981862B1 Lanthionine-related compounds for the treatment of inflammatory diseases |
| 03/02/2011 | EP1966146B1 4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators |
| 03/02/2011 | EP1694654B1 Substituted triazoles as sodium channel blockers |
| 03/02/2011 | EP1638552B1 Use of (3.2.0) heterocyclic compounds and analogs thereof for the treatment of cancer |
| 03/02/2011 | EP1581518B1 Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 03/02/2011 | EP1513846B1 Process of preparation of olanzapine form i |
| 03/02/2011 | EP1511489B1 New pharmaceutical compositions containing flibanserin polymorph a |
| 03/02/2011 | EP1383761B1 Phenyl- and pyridyl-piperidines with tnf activity |
| 03/02/2011 | EP1248613B1 Clonidine preparations |
| 03/02/2011 | CN101983193A Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder |
| 03/02/2011 | CN101983074A Use of pegylated igf-i variants for the treatment of neuromuscular disorders |
| 03/02/2011 | CN101983058A Compositions and methods for alleviating depression or improving cognition |
| 03/02/2011 | CN101983052A Galenic form for the oral transmucosal delivery of triptans |
| 03/02/2011 | CN101982471A Technological process for extracting aucubin from fruits of eucommia ulmoides oliver |
| 03/02/2011 | CN101982170A Amide compound and application thereof in preparing monoamine oxidase inhibitor |
| 03/02/2011 | CN101982168A Quercetin nano-micelle preparation and preparation method thereof |
| 03/02/2011 | CN101982139A Pillow with hypnotic effect |
| 03/02/2011 | CN101982138A Medicine pillow for refreshing mind and dispelling stagnation |
| 03/02/2011 | CN101322709B Medicament composition containing aripiprazole and preparation thereof |
| 03/02/2011 | CN101305011B Pyridine derivatives and their use in the treatment of psychotic disorders |
| 03/02/2011 | CN101171235B Dipyrazoles as central nervous system agents |
| 03/02/2011 | CN101084225B Isoxazoline-indole derivatives with an improved antipsychotic and anxiolytic a ivity |
| 03/02/2011 | CN101035760B Compounds which potentiate glutamate receptor and uses thereof in medicine |
| 03/01/2011 | US7897757 for treating, preventing, inhibiting, or reducing obesity, insulin resistance, diabetes and any other disease, trait, or condition that is related to or will respond to the levels of PTP-1B in a cell or tissue |
| 03/01/2011 | US7897729 Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors |
| 03/01/2011 | US7897644 Antiinflammatory agents; analgesics |
| 03/01/2011 | US7897618 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 03/01/2011 | US7897603 Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions |
| 03/01/2011 | US7897384 Chondrocyte therapeutic delivery system |
| 03/01/2011 | US7897180 Enamel matrix protein composition for treatment of systemic inflammatory response |
| 03/01/2011 | US7897173 Tramadol hydrochloride with such as diclofenac sodium; reduced water solubility |
| 03/01/2011 | US7897157 Polypeptides with a functional binding domain, translocation domain, a therapeutic domain and a non-native protease cleavage site for cleavage in vitro following expression as a single chain; efficient, less dangerous production method; botulinum neurotoxins targeted to specific cell types |
| 03/01/2011 | CA2626646C Carbazole derivatives as functional 5-ht6 ligands |
| 03/01/2011 | CA2602348C Cyclopentapyridine and tetrahydroquinoline derivatives |
| 03/01/2011 | CA2512187C Use of derivatives of succinate esters for the treatment of dementia |
| 03/01/2011 | CA2511974C Pharmaceutical compositions comprising fentanyl for intranasal delivery |
| 03/01/2011 | CA2490878C Indole derivative and drug containing the same |
| 02/24/2011 | WO2011022638A1 Trp inhibitors and uses thereof |
| 02/24/2011 | WO2011022606A2 Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
| 02/24/2011 | WO2011022462A2 Neural regeneration |
| 02/24/2011 | WO2011022348A1 Ethylene diamine modulators of fatty acid amide hydrolase |
| 02/24/2011 | WO2011022292A2 Method of treating bipolar disorder or depression using an antiestrogen |
| 02/24/2011 | WO2011022045A2 Apparatus and process for generating and harvesting adult stem cells and fluid associated with it from skin and omentum for medical, cosmetic, and veterinary use |
| 02/24/2011 | WO2011021979A1 Cinnoline compounds, their preparation, and their use |
| 02/24/2011 | WO2011021916A2 Use of egf-like domain of heregulin beta 1 peptide |
| 02/24/2011 | WO2011021832A2 Composition for preventing or treating a spinal cord injury |
| 02/24/2011 | WO2011021678A1 Fused heterocyclic compound |
| 02/24/2011 | WO2011021645A1 Bicyclic urea derivative or pharmacologically permitted salt thereof |
| 02/24/2011 | WO2011020193A1 Renin inhibitors |